AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Study ID
STU 102014-066

Study Sites

  • Children’s Medical Center (Dallas, Plano, Southlake)

Contact
Princess Iroh
214-590-0608
princess.iroh-rodgers@childrens.com

Principal Investigator
Tamra Slone, M.D.

Summary

See protocol/CiRB application

Participant Eligibility

See protocol